Cornel Popovici

Dr. Cornel Popovici

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2003 in Cell
Verified
Journal Article
Closed access
VBVincent Bertrand
Vincent Bertrand
CHClare Hudson
Clare Hudson
DCDanielle Caillol
Danielle Caillol
CPCornel Popovici
Cornel Popovici
PLPatrick Lemaire
Patrick Lemaire

2 May 2007 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SFStéphanie Fabre-Lafay
Stéphanie Fabre-Lafay
FMFlorence Monville
Florence Monville
SGSarah Garrido-Urbani
Sarah Garrido-Urbani
CBCarole Berruyer-Pouyet
Carole Berruyer-Pouyet
CGChristophe Ginestier
Christophe Ginestier
MLMarc Lopez
Marc Lopez
Introduction: Breast cancer is a complex and heterogeneous disease at the molecular level. Evolution is difficult to predict according to classical histoclinical prognostic factors. Different studies highlight the importance of large-scale molecular expression analyses to improve taxonomy of breast cancer and prognostic classification. Identification of new molecular markers that refine this taxonomy and improve patient management is a priority in the field of breast cancer research.Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma.Methods: Expression of Nectin-4 protein was measured on a panel of 78 primary cells and cell lines from different origins and 57 breast tumors by FACS analysis and immunohistochemistry (IHC), respectively. mRNA expression was measured by quantitative PCR.Serum Nectin-4 was detected by ELISA and compared with CEA and CA15.3 markers, on panels of 45 sera from healthy donors, 53 sera from patients with non-metastatic breast carcinoma (MBC) at diagnosis, and 182 sera from patients with MBC. Distribution of histological/serological molecular markers and histoclinical parameters were compared using the standard Chi-2 test.Results: Nectin-4 was not detected in normal breast epithelium. By contrast, Nectin-4 was expressed in 61% of ductal breast carcinoma vs 6% in lobular type. Expression of Nectin-4 strongly correlated with the basal-like markers EGFR, P53, and P-cadherin, and negatively correlated with the luminal-like markers ER, PR and GATA3. All but one ER/PR-negative tumors expressed Nectin-4. The detection of Nectin-4 in serum improves the follow-up of patients with MBC: the association CEA/CA15.3/Nectin-4 allowed to monitor 74% of these patients compared to 67% with the association CEA/CA15.3. Serum Nectin-4 is a marker of disease progression, and levels correlate with the number of metastases (P= 0.038). Serum Nectin-4 is also a marker of therapeutic efficiency and correlates, in 90% of cases, with clinical evolution.Conclusion: Nectin-4 is a new tumor-associated antigen for breast carcinoma. Nectin-4 is a new bio-marker whose use could help refine breast cancer taxonomy and improve patients' follow-up. Nectin-4 emerges as a potential target for breast cancer immunotherapy.

12 May 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CPCornel Popovici
Cornel Popovici
JAJosé Adélaïde
José Adélaïde
VOVincent Ollendorff
Vincent Ollendorff
MCMax CHAFFANET
Max CHAFFANET
GGGeraldine Guasch
Geraldine Guasch
MPMarie-Josèphe Pébusque
Marie-Josèphe Pébusque
Chromosome 8p11–12 is the site of a recurrent breakpoint in a myeloproliferative disorder that involves lymphoid (T- or B-cell), myeloid hyperplasia and eosinophilia, and evolves toward acute leukemia. This multilineage involvement suggests the malignant transformation of a primitive hematopoietic stem cell. In this disorder, the 8p11–12 region is associated with three different partners 6q27, 9q33, and 13q12. We describe here the molecular characterization of the t(8;13) translocation that involves the FGFR1 gene from 8p12, encoding a tyrosine kinase receptor for members of the fibroblast growth factor family, and a gene from 13q12, tentatively named FIM ( F used I n M yeloproliferative disorders). FIM is related to DXS6673E , a candidate gene for X-linked mental retardation in Xq13.1; this defines a gene family involved in different human pathologies. The two reciprocal fusion transcripts, FIM/FGFR1 and FGFR1/FIM are expressed in the malignant cells. The FIM/FGFR1 fusion protein contains the FIM putative zinc finger motifs and the catalytic domain of FGFR1. We show that it has a constitutive tyrosine kinase activity.

15 February 2011 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
FSFabrice Sircoulomb
Fabrice Sircoulomb
NNNathalie Nicolas
Nathalie Nicolas
AFAnthony Ferrari
Anthony Ferrari
PFPascal FINETTI
Pascal FINETTI
IBIsmahane Bekhouche
Ismahane Bekhouche
CGChristophe Ginestier
Christophe Ginestier
Luminal B breast cancers represent a fraction of oestrogen receptor (ER)‐positive tumours associated with poor recurrence‐free and disease‐specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B biology is paramount to improve treatment. We have studied 100 luminal breast tumours by combined analysis of genome copy number aberrations and gene expression. We show that amplification of the ZNF703 gene, located in chromosomal region 8p12, preferentially occurs in luminal B tumours. We explored the functional role of ZNF703 in luminal B tumours by overexpressing ZNF703 in the MCF7 luminal cell line. Using mass spectrometry, we identified ZNF703 as a co‐factor of a nuclear complex comprising DCAF7, PHB2 and NCOR2. ZNF703 expression results in the activation of stem cell‐related gene expression leading to an increase in cancer stem cells. Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis. →See accompanying Closeup by Vessela Kristensen DOI 10.1002/emmm201100128

13 July 2005 in BioEssays
Verified
Journal Article
Closed access
PDF file
CPCornel Popovici
Cornel Popovici
RRRégine Roubin
Régine Roubin
FCFrançois Coulier
François Coulier
DBDaniel Birnbaum
Daniel Birnbaum

1 January 2003 in Blood
Verified
Journal Article
Closed access
PDF file
GGGeraldine Guasch
Geraldine Guasch
CPCornel Popovici
Cornel Popovici
FMFrancine Mugneret
Francine Mugneret
MCMax CHAFFANET
Max CHAFFANET
Pierre PontarottiPierre Pontarotti
Pierre Pontarotti
MPMarie-Josèphe Pébusque
Marie-Josèphe Pébusque
FGFR1, a transmembrane receptor tyrosine kinase for fibroblast growth factors, is constitutively activated by chromosomal translocations in an atypical stem-cell myeloproliferative disorder. The FGFR1 tyrosine domain is fused to dimerization domains encoded by 4 alternative genes: FOP at 6q27, CEP110 at 9q33,FIM/ZNF198 at 13q12, and BCR at 22q11. In this study, we report the molecular cloning of the t(8;19)(p12;q13.3), the fifth translocation associated with this syndrome. Reverse transcriptase–polymerase chain reaction (RT-PCR) analysis and fluorescence in situ hybridization (FISH) demonstrated that the translocation resulted in a long terminal repeat of human endogenous retrovirus gene (HERV-K)/fibroblast growth factor receptor 1 (FGFR1) fusion transcript that incorporated 5′ sequences from HERV-K fused in frame to 3′ FGFR1 sequences encoding the kinase domain. RT-PCR detected only 1 of the 2 possible fusion transcripts,HERV-K/FGFR1.